Enjamb LabsSpring 2026Active☆Watch⊞Compare

Enjamb Labs is one of 310 Pharma companies tracked from San Francisco, CA, USA, on record since 2026. By capital raised it ranks in the long tail (ahead of 16% of sector peers), and in the long tail by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

AI analyst read est. — model-extracted from this company's public description, not a verified fact. 30%

operates a technology-led product inferred from public copy

Grounded in: “You are a venture analyst”

Where drug teams run their entire program, discovery to FDA approval

Enjamb runs the entire drug program for biopharma teams, from discovery to FDA approval. Pharma runs on decades of closed legacy systems like Benchling, Veeva, Medidata, and SAS, with no AI layer and no MCP to connect agents to them. So we built that connection layer in one platform. Our agents run on top of their existing systems and data, with no migration, and do the work across the whole program: clinical evidence, trial design, statistical programming, and regulatory submissions. In just 3 weeks since launch, we're already being used by 500+ employees at top pharma companies, including Johnson & Johnson, AbbVie, Bristol Myers Squibb, Merck & Sanofi.

As reported in public records reported — not modeled.

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

No round amounts on record to chart.

No staged rounds to sequence.

Round size and date are reported; the stage label is inferred from round size. Valuation is modeled from stage benchmarks. Directional, not a quoted figure.

Not enough modeled valuation points to chart a trajectory.

Benchmarked against 310 companies in Pharma. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Raised more than 16% of sector peers (real $). Modeled value above 16% of peers (estimate).

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Enjamb Labs is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

See where Enjamb Labs sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

If you work at Enjamb Labs, claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.